Skip to main content
. Author manuscript; available in PMC: 2020 Jun 30.
Published in final edited form as: Clin Cancer Res. 2018 Mar 7;24(11):2585–2593. doi: 10.1158/1078-0432.CCR-17-3811

Figure 3.

Figure 3.

Biodistribution profile of SN38-TOA nanoparticles (NP). Mice (n = 3/arm, per time point) were given a single dose of SN38-TOA nanoparticles (10 mg/kg) or CPT-11 (25 mg/kg) intravenously via tail vein. A and B, Blood: SN38-TOA nanoparticle treated (A) and CPT-11 treated (B). C and D, Tumor, SN38-TOA nanoparticle treated (C) and CPT-11 treated (D) were collected post sacrifice at 4, 24, and 72 hours. SN38 levels in SN38-TOA nanoparticle-treated mice were much higher compared with CPT-11–treated mice at all time points. Values are shown ±SE.